Sirolimus

Introduction Overview

Generic Name

sirolimus

Brand Name

Rapamune

Dosage Form

Oral tablet, Oral liquid

Drug Class

mTOR inhibitors, Selective immunosuppressants

Pharmacokinetics

Absorption: Sirolimus is rapidly absorbed following oral administration with bioavailability that is generally variable and influenced by food intake; high-fat meals may significantly reduce its absorption. The Tmax typically occurs between 1 and 2 hours post-dose. Because of its narrow therapeutic index and variable oral bioavailability, careful dosing and monitoring are essential. Extensive first-pass metabolism in the gut and liver contribute to the drug's bioavailability variability.

Distribution: Sirolimus is highly lipophilic and extensively distributed throughout the body's tissues. It exhibits a large volume of distribution (ranging approximately 12 L/kg), indicating extensive tissue binding. In plasma, sirolimus binds primarily to albumin and lipoproteins with over 90% being protein-bound, which affects its pharmacokinetic behavior. The drug crosses cellular membranes and concentrates in lymphoid tissues, consistent with its immunosuppressive action.

Metabolism: Sirolimus undergoes extensive hepatic metabolism primarily via the cytochrome P450 3A4 (CYP3A4) enzyme system. It is also a substrate of P-glycoprotein (P-gp), which modulates its absorption and excretion. Metabolic pathways include demethylation and hydroxylation, resulting in multiple inactive metabolites. Drug-drug interactions involving CYP3A4 or P-gp inhibitors or inducers significantly affect sirolimus plasma concentrations, necessitating dose adjustments and therapeutic drug monitoring.

Elimination: The elimination of sirolimus is predominantly biliary, with less than 2% excreted unchanged in urine. The terminal half-life in stable renal transplant recipients is approximately 60 hours, but may vary widely among individuals and clinical conditions. Fecal excretion accounts for the majority of drug elimination. The prolonged half-life supports once-daily dosing regimens. Therapeutic drug monitoring is critical to maintain efficacious and safe plasma concentrations, minimizing toxicity and rejection risks.

Dosage Forms

Available Dosage Forms: Rapamune is available as oral tablets and oral liquid formulations. The oral tablet strengths include 1 mg, 2 mg, and 5 mg. The oral liquid is available as 1 mg/mL solution.

Dosages for Adults and Adolescents: For kidney transplant rejection prophylaxis in adults and adolescents aged 13 years and older, dosing is based on body weight and immunologic risk. Patients ≥40 kg typically receive a loading dose of 6 mg orally on day 1, followed by a maintenance dose of 2 mg once daily. Those <40 kg receive a loading dose of 3 mg/m² on day 1, then 1 mg/m² daily maintenance. High-immunologic risk adults may require higher loading doses (up to 15 mg) and maintenance doses, with dose adjustments based on trough concentration monitoring. For pulmonary lymphangioleiomyomatosis (LAM), the initial adult dose is 2 mg/day, adjusted to maintain whole blood trough levels between 5 and 15 ng/mL.

Specific Patient Populations: Pediatric patients aged 13 years and older follow similar weight-based dosing as adults. Patients with impaired hepatic function may exhibit altered metabolism requiring dose modification. Dose adjustments are necessary when Rapamune is administered concomitantly with drugs affecting CYP3A4 or P-gp activity. Careful dose titration and therapeutic drug monitoring are recommended in renal, hepatic impairment, and older adult populations to optimize safety and efficacy. Cyclosporine withdrawal after combined therapy may require up to a fourfold increase in sirolimus dosage to maintain immunosuppression due to metabolic changes.

Mechanism Of Action

Sirolimus (rapamycin), the active constituent of Rapamune, exerts its immunosuppressive effects primarily by inhibiting the mammalian target of rapamycin (mTOR), a serine/threonine kinase central to cellular growth, proliferation, and survival pathways. Upon entering cells, sirolimus forms a complex with the immunophilin FK-binding protein 12 (FKBP12). This complex then binds to and inhibits mTOR complex 1 (mTORC1), blocking downstream signaling pathways essential for cell cycle progression from G1 to S phase.

This inhibition selectively suppresses T-lymphocyte activation and proliferation in response to cytokines such as interleukin-2 (IL-2), interleukin-4 (IL-4), and interleukin-15 (IL-15). By impairing these key signals, sirolimus effectively decreases immune responses responsible for graft rejection without directly depleting T cells, thus offering a selective immunomodulatory effect.

Beyond immunosuppression, mTOR inhibition affects vascular endothelial growth factor (VEGF)-mediated angiogenesis, which contributes to its antiproliferative and antineoplastic properties. This explains the drug’s utility in treating lymphangioleiomyomatosis (LAM), where abnormal smooth muscle cell growth in the lungs is controlled.

Research has demonstrated that sirolimus differs mechanistically from calcineurin inhibitors like tacrolimus and cyclosporine by targeting downstream intracellular signaling rather than blocking T-cell receptor signaling at the membrane level. Clinical trials highlight its synergy with calcineurin inhibitors and corticosteroids in transplant immunosuppression regimens, offering distinct pharmacodynamic profiles and complementary effects. This unique mode of action contributes to improved graft survival and modulation of immune responses.

Pharmacological Actions

Immunosuppressive effect via selective inhibition of T-lymphocyte activation and proliferation.
Inhibition of mTOR complex 1, resulting in cell cycle arrest in the G1 phase.
Suppression of cytokine-driven immune responses, particularly IL-2 mediated T-cell activation.
Anti-proliferative action on vascular smooth muscle cells and inhibition of angiogenesis.
Reduction of antibody formation against transplanted organs, decreasing graft rejection risk.
Immunomodulatory properties beneficial in treatment of lymphangioleiomyomatosis by limiting abnormal smooth muscle lung proliferation.
Long half-life and potent tissue distribution facilitating once-daily dosing.
Minimal nephrotoxicity compared to calcineurin inhibitors.
Synergistic effects with cyclosporine and corticosteroids in transplant immunosuppression protocols.
Modulation of immune cell metabolism impacting overall immune system activity.
Potential antiproliferative effects with emerging roles in certain malignancies.
Action on mTOR pathway influencing both innate and adaptive immune responses.
Reduced risk of acute rejection episodes when used as part of combination therapy.

Therapeutic Or Clinical Uses

Prevention of organ rejection in kidney transplant recipients aged 13 years and older.
Adjunct immunosuppressive therapy combined with cyclosporine and corticosteroids post-transplant.
Treatment of lymphangioleiomyomatosis (LAM) to control abnormal lung tissue proliferation.
Maintenance immunosuppression in organ transplant recipients at low to moderate immunologic risk.
Management of high immunologic risk transplant patients with dose adjustments and monitoring.
Utilized in regimens aiming to minimize calcineurin inhibitor nephrotoxicity by cyclosporine withdrawal.
Immunosuppressive strategies to reduce T-cell mediated rejection without compromising kidney function.
Potential investigational applications in other transplant types (excluding lung and liver transplants).
Research into antiproliferative and antineoplastic potential in certain rare tumors.
May be useful in treating disorders with aberrant mTOR pathway activation.

Side Or Adverse Effects

Increased susceptibility to infections including viral, bacterial, and fungal types due to immunosuppression.
Serious brain infections such as progressive multifocal leukoencephalopathy (PML) that can cause disability or death.
Overproduction of white blood cells leading to increased risk of certain cancers, including skin malignancies.
Common adverse effects including fever, sore throat, and cold-like symptoms.
Mouth ulcers or sores causing discomfort and potential difficulty eating.
Gastrointestinal disturbances such as nausea, stomach pain, diarrhea.
Headache and muscle aches frequently reported during therapy initiation.
Chest pain and dizziness, warranting clinical evaluation.
Acneiform eruptions and rash; careful monitoring for new or changing skin lesions advised.
Anemia manifesting as pale skin, fatigue, and shortness of breath.
Unusual bleeding or bruising due to hematologic effects.
Delayed wound healing and risk of skin wound infections.
Potential allergic reactions including hives, swelling, difficulty breathing.
Neurologic symptoms including changes in mental status, vision disturbances, weakness, speech or gait difficulties requiring emergent attention.
Elevation in cholesterol and triglyceride levels.

Precautions

Avoid use in patients who have had lung or liver transplants due to increased risk of adverse outcomes.
Monitor carefully for signs and symptoms of infection; immediately report any fever, chills or flu-like symptoms.
Regular screening for skin cancer and protection from sunlight due to increased risk.
Use effective contraception during treatment and for at least 12 weeks post-therapy as sirolimus is teratogenic.
Do not breastfeed while taking sirolimus due to potential drug excretion into breast milk.
Adjust dosing cautiously in patients with hepatic impairment due to metabolism dependence.
Avoid grapefruit and grapefruit juice as they can increase sirolimus blood concentrations via CYP3A4 inhibition.
Monitor lipid panels as sirolimus can increase cholesterol and triglycerides.
Avoid live vaccines during therapy as immune response may be inadequate and risk of infection increased.
Do not abruptly discontinue therapy to prevent risk of rejection flare or disease exacerbation.
Use caution in patients with history of hyperlipidemia or cytomegalovirus infection.
Ensure frequent therapeutic drug monitoring to maintain optimal sirolimus levels and minimize toxicity.
Avoid exposure to individuals with contagious illnesses to reduce infection risk.
Use caution in renal impairment; monitor renal function closely.
Counsel patients on signs of allergic reactions and neurologic changes for prompt management.

Warnings

Contraindicated in patients with prior liver or lung transplants due to safety concerns.
Potential to cause severe infections including fatal brain infection (e.g., PML).
Increased risk of malignancies, especially skin cancers, requiring regular dermatologic evaluations.
May cause overproduction of white blood cells leading to hematologic malignancies.
Associated with kidney transplant failure if viral infections develop during treatment.
Risk of impaired wound healing and increased susceptibility to wound infections.
Requires stringent immunosuppressive monitoring to avoid rejection due to variable plasma levels.
Use with caution in diabetics and those at risk of hyperlipidemia or hyperglycemia.
Fatal complications can occur if therapy is stopped abruptly or doses missed.
Concomitant use with certain drugs can dangerously increase sirolimus levels and toxicity.
Live vaccines are contraindicated due to compromised immune response.
Patients should promptly report neurologic symptoms such as weakness, vision loss, confusion, or speech difficulty.
Use in pediatric patients limited to those aged 13 years and older; safety not established in younger children.
Pregnancy category contraindicates use during pregnancy; associated with potential fetal harm.
Storage warnings: oral liquid should be refrigerated and protected from freezing; tablets stored at room temperature.

Contraindication

Known hypersensitivity or allergy to sirolimus or any component of Rapamune formulations.
Prior history of lung transplantation.
Prior history of liver transplantation.
Pregnancy due to teratogenic effects and fetal risk.
Concurrent use of live vaccines such as MMR, varicella, yellow fever, and others.
Severe infections or active uncontrolled infections at the time of treatment initiation.
Use in pediatric patients under 13 years of age is contraindicated due to lack of safety data.
Known hypersensitivity to any excipients in the oral liquid or tablet formulations.
Patients with known hypersensitivity to rapamycin derivatives or mTOR inhibitors.

Drug Interactions

Contradicted or cautioned with CYP3A4 and P-glycoprotein inhibitors or inducers affecting sirolimus metabolism (e.g., ketoconazole, erythromycin, rifampin).
Concurrent administration with cyclosporine requires staggered dosing (at least 4 hours apart) and may require dose adjustment.
Interactions with other immunosuppressants such as tacrolimus warrant monitoring for additive immunosuppression.
Drugs affecting lipid metabolism (cholesterol-lowering agents) must be monitored due to sirolimus induced dyslipidemia.
Antibiotics and antifungal agents (e.g., clarithromycin, fluconazole) can increase sirolimus blood levels.
Anti-viral drugs used in HIV or hepatitis C can significantly affect sirolimus metabolism.
Heart or blood pressure medications may have altered effects or enhance side effects.
Gastrointestinal acid reducers such as proton pump inhibitors may influence sirolimus bioavailability.
Seizure medications, many being CYP450 inducers, can decrease sirolimus levels and reduce efficacy.
Herbal supplements like St. John's wort significantly induce CYP3A4, reducing sirolimus plasma concentration.
Bromocriptine and danazol have potential interaction through metabolic pathways.
Drugs that impair immune function or blood cell counts require caution to avoid additive immunosuppression.
Grapefruit and grapefruit juice are contraindicated due to potent CYP3A4 inhibition increasing sirolimus toxicity risk.
Interactions with vaccination drugs, live vaccines are contraindicated during therapy.
Any new medications or over-the-counter supplements should be reviewed for potential interactions with sirolimus.

Preparations Of The Drug

Oral tablets available in strengths of 1 mg, 2 mg, and 5 mg for extended release formulation.
Oral liquid formulation containing 1 mg/mL sirolimus, to be mixed only with water or orange juice.
Tablets should be swallowed whole; crushing, chewing, or breaking the tablet is contraindicated.
Oral liquid must be carefully measured using the provided dosing syringe or an appropriate measuring device; kitchen utensils are inadequate.
Oral liquid requires refrigeration at 2°C to 8°C (36°F to 46°F) and should not be frozen; slight haze on the liquid is acceptable and dissipates at room temperature.
Loaded oral liquid syringes can be stored in the protective case at room temperature but must be used within 24 hours.
Storage of tablets recommended at room temperature, protected from heat, moisture, and light.
Dosing instructions include taking sirolimus consistently with regard to food, either always with or always without food to maintain consistent absorption.
Proper disposal protocols for used oral syringes to prevent accidental dosing errors or contamination.
Commercially marketed as Rapamune by Pfizer with strict quality control standards.
Accompanying patient information leaflets detail administration, storage, and precautions.
Packaging provided includes blister packs for tablets and amber bottles with dosing syringes for oral liquid.
Preparation instructions caution against mixing oral liquid with any liquids other than water or orange juice.
Availability of generic formulations of sirolimus with equivalent pharmacologic activity and dosage forms.